CA2341400A1 - Procedes et compositions employant le vigabatrin s(+) optiquement pur - Google Patents

Procedes et compositions employant le vigabatrin s(+) optiquement pur Download PDF

Info

Publication number
CA2341400A1
CA2341400A1 CA002341400A CA2341400A CA2341400A1 CA 2341400 A1 CA2341400 A1 CA 2341400A1 CA 002341400 A CA002341400 A CA 002341400A CA 2341400 A CA2341400 A CA 2341400A CA 2341400 A1 CA2341400 A1 CA 2341400A1
Authority
CA
Canada
Prior art keywords
vigabatrin
administered
pharmaceutically acceptable
acceptable salt
stereoisomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002341400A
Other languages
English (en)
Inventor
Paul D. Rubin
Timothy J. Barberich
William E. Yelle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2341400A1 publication Critical patent/CA2341400A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des procédés et compositions pour la prévention, le traitement et/ou la gestion des symptômes de neuropathie périphérique et d'affections connexes, de narcomanie ou d'alcoolisme ou leurs symptômes, ou des symptômes associés au sevrage alcoolique ou au sevrage de drogue, utilisant du vigabatrin S(+) optiquement pur, ou un sel de celui-ci pharmaceutiquement acceptable.
CA002341400A 1998-08-25 1999-08-24 Procedes et compositions employant le vigabatrin s(+) optiquement pur Abandoned CA2341400A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9778698P 1998-08-25 1998-08-25
US60/097,786 1998-08-25
US11445698P 1998-12-30 1998-12-30
US60/114,456 1998-12-30
PCT/US1999/019346 WO2000010554A2 (fr) 1998-08-25 1999-08-24 Procedes et compositions employant le vigabatrin s(+) optiquement pur

Publications (1)

Publication Number Publication Date
CA2341400A1 true CA2341400A1 (fr) 2000-03-02

Family

ID=26793638

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002341400A Abandoned CA2341400A1 (fr) 1998-08-25 1999-08-24 Procedes et compositions employant le vigabatrin s(+) optiquement pur

Country Status (5)

Country Link
EP (1) EP1107748A2 (fr)
JP (1) JP2003520189A (fr)
AU (1) AU5784499A (fr)
CA (1) CA2341400A1 (fr)
WO (1) WO2000010554A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100179215A1 (en) 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders
US20100179214A1 (en) 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin trans isomers and isomeric mixtures and methods of using the same to treat sleep disorders
CA2687118A1 (fr) 2006-05-19 2007-12-13 Somaxon Pharmaceuticals, Inc. Procedes d'utilisation de doxepine faiblement dosee pour ameliorer le sommeil
US20080058408A1 (en) 2006-05-19 2008-03-06 Rogowski Roberta L Low-dose doxepin for treatment of sleep disorders in elderly patients
WO2008011150A1 (fr) 2006-07-20 2008-01-24 Somaxon Pharmaceuticals, Inc. Méthodes destinées à améliorer la pharmacocinétique de la doxépine
US20100105614A1 (en) 2006-10-25 2010-04-29 Somaxon Pharmaceuticals, Inc. Ultra low dose doxepin and methods of using the same to treat sleep disorders
WO2008070795A2 (fr) 2006-12-06 2008-06-12 Somaxon Pharmaceuticals, Inc. Polythérapie utilisant de la doxépine à faible dose pour l'amélioration du sommeil
WO2008128115A2 (fr) 2007-04-13 2008-10-23 Somaxon Pharmaceuticals, Inc. Formulations de doxépine à faible dose et procédé de préparation et d'utilisation de celle-ci
EP3426230A1 (fr) * 2016-03-10 2019-01-16 Orphelia Pharma Formes galéniques solides de vigabatrine
CN110869003A (zh) * 2019-01-28 2020-03-06 上海奥科达生物医药科技有限公司 一种不含防腐剂的固体剂型氨己烯酸药物组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2133002B (en) * 1982-12-30 1986-01-29 Merrell Toraude & Co Process for preparing 4-amino-5-hexenoic acid
US4595697A (en) * 1984-03-28 1986-06-17 Merrell Dow Pharmaceuticals Inc. Treatment of seizure disorders and pharmaceutical compositions useful therein
EP0509180A1 (fr) * 1991-04-18 1992-10-21 Merrell Dow Pharmaceuticals Inc. Utilisation d'inhibiteurs de la GABA-T pour le traitement de la schizophrenie et l'intoxication de la phencyclidine
US6541520B1 (en) * 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior

Also Published As

Publication number Publication date
JP2003520189A (ja) 2003-07-02
WO2000010554A3 (fr) 2000-11-30
AU5784499A (en) 2000-03-14
EP1107748A2 (fr) 2001-06-20
WO2000010554A2 (fr) 2000-03-02

Similar Documents

Publication Publication Date Title
CN104958282B (zh) 他喷他多组合物
AU770777B2 (en) Multilayered tablet for administration of a fixed combination of tramadol and diclofenac
CA2618212C (fr) Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte et son application therapeutique
MXPA06011648A (es) Metodos para uso de composiciones de aminopiridina de liberacion sostenida.
US20080031950A1 (en) Novel anelgesic combination
JP2007526277A (ja) 経口投与を目的としたトルペリゾンの徐放性医薬組成物
KR20090017593A (ko) 새로운 라세카도트릴의 투여 방법
AU758181B2 (en) Therapeutic agents
CN1141937C (zh) 含有曲马朵的药物组合物用于制备治疗偏头痛或类偏头痛的药物
CA2341400A1 (fr) Procedes et compositions employant le vigabatrin s(+) optiquement pur
MXPA06004327A (es) Composiciones y forma de dosificacion para el efecto retardado de levodopa.
JP2003521469A (ja) 睡眠時無呼吸症を治療する方法
EP1345610A1 (fr) Procede de traitement
AU773490B2 (en) Treatment of osteoarthritis
TW200812579A (en) Treatment of pain
WO2000056311A1 (fr) Regulation du metabolisme
JP2002539254A (ja) 血小板粘着性を低下させるための治療
EP4070793A1 (fr) Composition pharmaceutique, trousse complémentaire et son application
RU2354378C1 (ru) Комбинированный противотуберкулезный препарат
JP2002539250A (ja) 肺高血圧症の治療
JP2002539255A (ja) 体重増加に関係する癌の治療
JP2002539252A (ja) 胆石の治療
MXPA00006201A (en) Pharmaceutical composition containing sibutramine and orlistat

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20030825